• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Pasithea Therapeutics Corp.

    6/29/22 4:30:24 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KTTA alert in real time by email
    SC 13G 1 ktta-sc13g_062222.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

     

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND

    (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2

    (Amendment No. )*

     

     

    Pasithea Therapeutics Corp.

    (Name of Issuer)

     

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

     

    70261F103

    (CUSIP Number)

     

     

    June 22, 2022

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

     

      ¨ Rule 13d-1(b)

     

      x Rule 13d-1(c)

     

      ¨ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

     

    CUSIP No. 70261F103 13G Page 2 of 10 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Paul B. Manning

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,608,6961

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,608,6961

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,608,6961

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.8%2

    12

    TYPE OF REPORTING PERSON*

    IN

     

      1 Consists of 2,608,696 shares of the Issuer’s common stock held directly by PD Joint Holdings, LLC, Series 2016-A.
      2 This percentage is calculated based upon 26,548,688 shares of the Issuer’s common stock outstanding as of June 22, 2022.

     

     
     

     

     

    CUSIP No. 70261F103 13G Page 3 of 10 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    PD Joint Holdings, LLC, Series 2016-A

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    2,608,696

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    2,608,696

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,408,696

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.8%3

    12

    TYPE OF REPORTING PERSON*

    OO

     

      3 This percentage is calculated based upon 26,548,688 shares of the Issuer’s common stock outstanding as of June 22, 2022

     

     

     
     

     

     

    CUSIP No. 70261F103 13G Page 4 of 10 Pages

    Item 1.

      (a) Name of Issuer

    Pasithea Therapeutics Corp

      (b) Address of Issuer’s Principal Executive Offices

    1111 Lincoln Road, Suite 500
    Miami Beach, Florida 33139

    Item 2.

      (a) Name of Person Filing

    Paul B. Manning
    PD Joint Holdings, LLC, Series 2016-A

      (b) Address of Principal Business Office or, if none, Residence

    c/o PBM Capital Group
    200 Garrett Street, Suite S
    Charlottesville, VA 22902

      (c) Citizenship

    Paul B. Manning is a United States Citizen.
    PD Joint Holdings, LLC, Series 2016-A is a Delaware limited liability company

      (d) Title of Class of Securities

    Common Stock

      (e) CUSIP Number

    70261F103

      Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: NOT APPLICABLE.

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
     
     

     

     

    CUSIP No. 70261F103 13G Page 7 of 10 Pages

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
    (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

      Item 4. Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

      (a) Amount beneficially owned: See responses to Item 9 on the attached cover pages.
      (b) Percent of class: See the responses to Item 11 on the attached cover pages.
      (c) Number of shares as to which the person has:
      (i) Sole power to vote or to direct the vote – See the responses to Item 5 on the attached cover pages.
      (ii) Shared power to vote or to direct the vote – See the responses to Item 6 on the attached cover pages.
      (iii) Sole power to dispose or to direct the disposition of – See the responses to Item 7 on the attached cover pages.
      (iv) Shared power to dispose or to direct the disposition of – See the responses to Item 8 on the attached cover pages.
             

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

      Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

      Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable

     

     
     

     

    CUSIP No. 70261F103 13G Page 8 of 10 Pages

     

      Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not Applicable

      Item 8. Identification and Classification of Members of the Group.

    Not Applicable

      Item 9. Notice of Dissolution of Group.

    Not Applicable

      Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. 

     
     

     

    CUSIP No. 70261F103 13G Page 9 of 10 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    June 29, 2022    
         
         
      /s/ Paul B. Manning  
      Paul B. Manning  
         
         
      PD Joint Holdings, LLC, Series 2016-A  
      By Tiger Lily Capital, LLC, its manager  
         
      By: /s/ Paul B. Manning  
      Name: Paul B. Manning  
      Title: Manager  
         
      By: /s/ Bradford Manning  
      Name: Bradford Manning  
      Title: Manager  
         
         

     

     

     

    Get the next $KTTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KTTA

    DatePrice TargetRatingAnalyst
    12/14/2021$3.25Buy
    EF Hutton
    More analyst ratings

    $KTTA
    SEC Filings

    View All

    SEC Form S-8 filed by Pasithea Therapeutics Corp.

    S-8 - Pasithea Therapeutics Corp. (0001841330) (Filer)

    1/30/26 4:15:51 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Corp. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)

    1/28/26 4:15:46 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Pasithea Therapeutics Corp.

    EFFECT - Pasithea Therapeutics Corp. (0001841330) (Filer)

    1/28/26 12:15:08 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Steinman Lawrence bought $100,000 worth of shares (133,333 units at $0.75), increasing direct ownership by 201% to 199,691 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 9:07:14 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Marques Tiago bought $25,000 worth of shares (33,333 units at $0.75), increasing direct ownership by 83% to 73,334 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 8:56:56 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dumesnil Simon bought $25,000 worth of shares (33,333 units at $0.75), increasing direct ownership by 1,333% to 35,833 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 8:54:08 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

    MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN), today provided updated timelines on its ongoing clinical trials in advanced cancer and adult NF1-PN patients. Ongoing Phase 1/1b clinical trial in adult patients with NF1-PN (NCT06961565): Pasithea has completed enrollment of 12 patients through the first 4 dose cohorts (4, 8, 12 and 18 mg tablets) in Part A of the study.    The Company plans to present data in the second half of

    1/13/26 7:01:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

    Extends cash runway through at least the first half of 2028Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners and Squadron Capital Management MIAMI, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ("Pasithea" or the "Company") (NASDAQ:KTTA, KTTAW)), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), today announced the closing of its previously announced public offering of 80,000,000 shares of the Company's common

    12/2/25 7:00:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

    Extends cash runway through at least the first half of 2028Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital Management MIAMI, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ("Pasithea" or the "Company") (NASDAQ:KTTA, KTTAW)), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), today announced the pricing of a public offering of 80,000,000 shares of the Company's common stock (or pre-funded warrants in lieu thereof) at an offering pr

    11/28/25 9:20:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Steinman Lawrence bought $100,000 worth of shares (133,333 units at $0.75), increasing direct ownership by 201% to 199,691 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 9:07:14 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Schneiderman Daniel H was granted 26,667 shares (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 9:04:30 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Marques Tiago bought $25,000 worth of shares (33,333 units at $0.75), increasing direct ownership by 83% to 73,334 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 8:56:56 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    EF Hutton initiated coverage on Pasithea Therapeutics with a new price target

    EF Hutton initiated coverage of Pasithea Therapeutics with a rating of Buy and set a new price target of $3.25

    12/14/21 8:32:07 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    Leadership Updates

    Live Leadership Updates

    View All

    Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

    MIAMI, June 11, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Dr. James Lee to its scientific advisory board (SAB) to help guide development of PAS-004 for the treatment of ETS2 pathway inflammatory diseases including inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, primary sclerosing cholangitis and ankylosing spondylitis. Dr. Lee is the lead author on a 2024 Nature publication that identified ETS2 as a central regulator of macrophage-driven inflammation in IBD and other indic

    6/11/25 7:02:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

    MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other indications, announced today that Rebecca Brown, M.D., Ph.D. has been appointed as a member of the Company's Scientific Advisory Board. Dr. Brown is currently Director of the Neurofibromatosis Clinic at The Mount Sinai Hospital and Assistant Professor in the Department of Neurology (Division of Neuro-Oncology), Internal Medicine, and Neurosurgery at the institution. Dr. Brown will contribute scientific insights

    9/3/24 8:02:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Announces Results from 2023 Annual Meeting

    SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ("Pasithea" or the "Company") (NASDAQ:KTTA), today announced that it held its annual meeting of stockholders (the "Annual Meeting") on December 19, 2023. Over 70% of the Company's shares of common stock were represented at the Annual Meeting. More than 95% of shares voted were cast "for" the election of directors (Proposal 1), and over 85% "for" Proposals 2, 3 and 6 (collectively, the "Approved Proposals"). The Approved Proposals related to the following matters: appointment of the Company's proposed slate of directors;-  Dr. Tiago Reis Marques;-  Prof. Larry Steinman;-  Simon Dume

    12/19/23 5:19:00 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    Financials

    Live finance-specific insights

    View All

    Pasithea Therapeutics Acquires AlloMek Therapeutics

    -- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor -- Plans to File IND Application with the FDA to Enter the Clinic in 2H 2023 -- Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 (NF1) -- Management to Host an Investor Webcast Today at 9 a.m. ET MIAMI BEACH, Fla., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, today announced that it acquired AlloMek Therapeutics, LLC ("AlloMek"), a privately-he

    10/12/22 8:00:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

    - Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases -- Expands pipeline across Pasithea's core therapeutic areas to drive enhanced growth -- Closing consideration of 3.26 million shares of Pasithea common stock -- Pasithea to hold a webcast on June 22 at 9 a.m. ET to discuss the transaction - MIAMI BEACH, Fla., June 22, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), today announced its acquisition of Alpha-5 integrin, LLC ("Alpha-5"), a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for the treatment of am

    6/22/22 8:00:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Pasithea Therapeutics Corp.

    SC 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)

    11/14/24 3:32:41 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pasithea Therapeutics Corp. (Amendment)

    SC 13G/A - Pasithea Therapeutics Corp. (0001841330) (Subject)

    1/13/23 8:02:14 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Pasithea Therapeutics Corp. (Amendment)

    SC 13D/A - Pasithea Therapeutics Corp. (0001841330) (Subject)

    1/10/23 3:55:25 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care